BIOQUAL, Inc. provides contract research services primarily focused on animal models of human diseases including acquired immunodeficiency syndrome (AIDS), influenza, respiratory syncytial virus (RSV) infection, coronavirus infections (including COVID-19), flavivirus infections (including Zika and Dengue), malaria, hepatitis, cancer, and other infectious diseases. It also performs in vitro contract research services. It is involved in the evaluation of vaccines, vaccine therapeutics, microbicides, and drug therapies. Its services also encompass sample processing and custom assays for serology, cell-mediated immunity, viral loads, and bacterial enumeration. Its model services also include syngeneic mouse tumor allograft and select human cell line derived xenograft (CDX) models, and it offers GLP-compliant preclinical testing services in various small animal models. It provides its services to the federal government, universities and the life science and pharmaceutical industries.